Use UniProt Q9NWZ3 as the stable identity anchor, then attach disease evidence before program review.
CHEMBL4523742 Target Snapshot
von Hippel-Lindau disease tumor suppressor/IRAK4 · PROTEIN-PROTEIN INTERACTION · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Protein identity stays anchored to UniProt Q9NWZ3. Use UniProt Q9NWZ3 as the stable identity anchor, then attach disease evidence before program review.
Interleukin-1 receptor-associated kinase 4
Review this target as von Hippel-Lindau disease tumor suppressor/IRAK4, mapped to UniProt Q9NWZ3. ChEMBL maps the protein component as Interleukin-1 receptor-associated kinase 4. Sequence length is 460 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats von Hippel-Lindau disease tumor suppressor/IRAK4 as ChEMBL target CHEMBL4523742, mapped to UniProt Q9NWZ3. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether von Hippel-Lindau disease tumor suppressor/IRAK4 is the right protein anchor across sources, using UniProt Q9NWZ3 as the stable mapping.
Jump to Protein ContextUse this block first when you need the strongest disease program and evidence level in one place.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | von Hippel-Lindau disease tumor suppressor/IRAK4 |
| Target Type | PROTEIN-PROTEIN INTERACTION |
| Organism | Homo sapiens |
| UniProt | Q9NWZ3 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Interleukin-1 receptor-associated kinase 4 |
| UniProt Accession | Q9NWZ3 |
| Component Type | Protein |
| Sequence Length | 460 aa |
Interleukin-1 receptor-associated kinase 4
How to read this target
Review this target as von Hippel-Lindau disease tumor suppressor/IRAK4, mapped to UniProt Q9NWZ3. ChEMBL maps the protein component as Interleukin-1 receptor-associated kinase 4. Sequence length is 460 aa.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4081711 | 7.8 | IC50 | 15.85 | Clinical |
| CHEMBL4521789 | 7.5 | IC50 | 31.62 | Preclinical |
pChEMBL Value Distribution
Assay Landscape
Binding — 22 assays, 2 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 17 | 2 | 7.4 |
| cell-based format | 5 | 0 | — |